Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.

Cancer research - 15 Mar 2011

Allen Thaddeus D, Zhu Chang Qi, Jones Kirk D, Yanagawa Naoki, Tsao Ming-Sound, Bishop J Michael

Abstract excerpt

MYC exerts both positive and negative functions in cancer cells, such that its procancerous effects are unmasked only after its anticancer effects are blocked. Here we used multiple mouse models of lung adenocarcinoma to identify genetic events that can cooperate with MYC activation to promote the genesis of non-small-cell lung cancer (NSCLC), the most common form of lung cancer in humans. MYC overexpression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hyperplasia
Share to In Situ Nick-End Labeling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Myeloid Cell Leukemia Sequence 1 Protein

Share to Outcome Assessment, Health Care

Share to Proto-Oncogene Proteins c-bcl-2

Share to Proto-Oncogene Proteins c-myc

Share to Pulmonary Alveoli

Share to Tissue Array Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 21406400
DOI: 10.1158/0008-5472.CAN-10-3590
PMCID: PMC3076947

Genes

MYC
MCL1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction between MYC and MCL1 in the genesis and outcome of non-small-cell lung cancer.PMID 21406400Read ↗

MCL-1 gains occur with high frequency in lung adenocarcinoma and can be targeted therapeutically.Semantic proximity Read ↗

Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.Semantic proximity Read ↗

C-myc Contributes to Malignancy of Lung Cancer: A Potential Anticancer Drug TargetSemantic proximity Read ↗

WT1 enhances proliferation and impedes apoptosis in KRAS mutant NSCLC via targeting cMyc.Semantic proximity Read ↗

Targeting Apoptotic Signaling Pathways in Human Lung CancerSemantic proximity Read ↗

MYC is a metastasis gene for non-small-cell lung cancer.Semantic proximity Read ↗

A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-rasSemantic proximity Read ↗

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.Semantic proximity Read ↗

Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.Semantic proximity Read ↗

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancerSemantic proximity Read ↗

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma.Semantic proximity Read ↗

Modelling Myc inhibition as a cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.